Data as of Dec 19
| +0.01 / +0.41%|
The 4 analysts offering 12-month price forecasts for CTi Biopharma Corp have a median target of 6.00, with a high estimate of 6.50 and a low estimate of 4.50. The median estimate represents a +145.90% increase from the last price of 2.44.
The current consensus among 4 polled investment analysts is to Buy stock in CTi Biopharma Corp. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.